Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirilumab and Nivolumab with Azacitidine in MDS
NCT02599649Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2016
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
A Phase 2 trial of lirilumab in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2016; status: terminated.
02
Drugs
lirilumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02599649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599649.